Aggressive Primary Cutaneous B Cell Lymphoma C5680500
A rare skin lymphoma originating from B cells that can grow and spread aggressively. It presents as skin lesions or nodules. Treatment may include radiation, chemotherapy, or immunotherapy depending on the stage.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Cutaneous nodules
(oncologic)Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Skin ulceration
(oncologic)B symptoms (fever, night sweats, weight loss)
(oncologic)Regional lymphadenopathy
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Localized Radiation Therapy
External beam radiation therapy targeting the affected skin lesions. This approach is highly effective for primary cutaneous lymphomas and offers excellent local control rates with minimal systemic side effects.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Surgical Excision
Complete surgical removal of affected skin lesions with appropriate margins. This provides immediate pathological confirmation and can be curative for solitary lesions.
Additional treatment options
Immunotherapy
Systemic immunotherapy agents that enhance the immune response against malignant B-cells. Used for multifocal or treatment-resistant disease to achieve durable remissions.
medicationPhototherapy
Narrowband UVB or PUVA therapy targeting proliferating lymphoma cells in the skin. A well-tolerated option for patients with multiple skin lesions who prefer non-invasive treatment.
procedureActive Surveillance
Regular dermatological monitoring with imaging for indolent or asymptomatic disease. Appropriate for selected patients with slowly progressive disease to avoid overtreatment.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Aggressive Primary Cutaneous B Cell Lymphoma C5680500?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022.
Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification: comparison with previous classifications and evaluation of interobserver agreement. J Clin Oncol. 2011.
Penchansky M, Pavlovsky C, Kohan E, et al. Efficacy of rituximab combined with chemotherapy in aggressive primary cutaneous B-cell lymphoma: a multicenter retrospective study. Blood Adv. 2019.
Grünhagen DJ, Noorduyn LA, Willemze R. The spectrum of primary cutaneous B-cell lymphoma: clinical and pathological features. J Cutan Pathol. 2015.
Medication Comparisons
Compare medications used to treat Aggressive Primary Cutaneous B Cell Lymphoma C5680500. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy